Search Press releases Keywords From To 3 Apr 2026 Acquisition of own shares Read More 31 Mar 2026 European Commission approves KYGEVVI[®]▼ (doxecitine and doxribtimine) as first and only treatment for Thymidine Kinase 2 Deficiency (TK2d) Read More 27 Mar 2026 Acquisition of own shares Read More 27 Mar 2026 UCB presents new BIMZELX[®] (bimekizumab-bkzx) data at AAD demonstrating high rates of durable and complete skin clearance in moderate-to-severe plaque psoriasis Read More 27 Mar 2026 UCB announces new BIMZELX[®] (bimekizumab-bkzx) data at AAD showing durable symptom control throughout three years in hidradenitis suppurativa Read More 27 Mar 2026 UCB Annual General Meeting of Shareholders 2026 Read More Pagination First page Previous page Previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Page 4 of 65 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
